SINO-U.S. Pharmaceutical Industry Summit 2011 Held with a Joint Declaration Signed
SINO-U.S. Pharmaceutical Industry Summit 2011 Held with a Joint Declaration Signed
——SINO-PhIRDA and PhRMA signed the Joint Declaration on Strengthening Intellectual Property Rights Protection, Promoting Pharmaceutical Industry Innovation and Development, and Improving Public Health
On October 18, the SINO-U.S. Pharmaceutical Industry Summit 2011 was grandly held in Beijing, which was cosponsored by the China Chamber of International Commerce (CCIOC), the China Pharmaceutical Industry Research and Development Association (SINO-PhIRDA), the American International Chamber of Commerce (AICC) and the Pharmaceutical Research and Manufactures of America (PhRMA). Thanks to the coordination and supports from the American Chamber of Commerce, the China Council for the Promotion of International Trade (CCPIT) and Fosun Pharma (Shanghai), more than 200 Chinese and foreign officials, corporate executives and industry experts attended the summit. The SINO-PhIRDA and the PhRMA signed the Joint Declaration on Strengthening Intellectual Property Rights Protection, Promoting Pharmaceutical Industry Innovation and Development, and Improving Public Health at the summit, in which both parties make commitments to constantly improve the health of the two peoples by providing safe and effective new drugs to patients. Both parties agreed that a complete intellectual property rights protection system is of crucial importance in the continuous innovations of biomedical industry and that they will fulfill their commitments to patients only through continuous innovations. To ensure continuous innovation in the pharmaceutical industry and promote the industry development, both sides proposed that they should urge the government departments to formulate and implement a series of supporting policies to protect various intellectual property rights in the pharmaceutical industry.
After reaching aforesaid consensuses, SINO-PhIRDA and PhRMA expressed that they would establish closer cooperation, assist government departments in formulating and implementing the intellectual property right protection system, and foster a policy environment for the research and development of safe, effective and technology-intensive new drugs. In addition, both sides promised to facilitate the constant improvement in legal system and enhance the protection on biomedical intellectual property rights in both countries by encouraging cooperation among all stakeholders.
The SINO-U.S. Pharmaceutical Industry Summit 2011 was cosponsored by the CCOIC, SINO-PhIRDA, AICC and PhRMA. Leaders of China’s Ministry of Commerce, Ministry of Health, State Food and Drug Administration (SFDA) and CCPIT attended and delivered speeches at the Summit, and over 200 enterprise representatives and experts in the pharmaceutical industry of both countries also attended the Summit.
Mr. Sang Guowei, Vice Chairman of the Standing Committee of the National People’s Congress (NPC) and Academician of the Chinese Academy of Engineering, and Christopher Viehbacher, Chairman of Board of PhRMA, also attended the Summit and delivered speeches.
At the Summit, Chinese and American experts gave speeches or keynote reports on pharmaceutical intellectual property rights protection, pharmaceutical industry innovation and development, health rights and interests of the social public and other topics. The cosponsors of the Summit also arranged the special Roundtable on Sino-U.S. Pharmaceutical Industry IPR Protection, at which Mr. Chen Qiyu, SINO-PhIRDA Vice President and Chairman of the Board of Fosun Pharma (Shanghai) introduced the status quo and future strategies of the company, attracting high attention from the industry.
The Summit also featured luncheon and banquet dinner for the sake of exchanges and communications among the participants and guests in a relaxing atmosphere. Wan Jifei, Chairman of the CCPIT and Chairman of the CCOIC, Jiang Zengwei, CPC Deputy Secretary and Vice Minister of Commerce of the PRC, and Wang Xiaomin, envoy of the U.S. Embassy in China and deputy head of the U.S. delegation, attended the luncheon and delivered speeches.
Two SINO-U.S. Pharmaceutical Industry Summits has been held twice since 2009. The Summit has become an important exchange platform for pharmaceutical industries in both China and the U.S., where industry representatives exchange opinions on the issues and strategies of public policies so as to promote the development of R&D-oriented pharmaceutical industries in both China and the U.S.
More than 30 news agencies including such mainstream media as Xinhua News Agency, People’s Daily, Bloomberg, Associated Press, Agence France Presse and Reuters sent journalists to report and interview the Summit, which received substantial supports from the AICC, the CCPIT, and Fosun Pharma (Shanghai) etc., as well as close cooperation from the R&D-based Pharmaceutical Association Committee (RDPAC).
About SINO-PhIRDA
Founded in 1988, China Pharmaceutical Industry Research and Development Association (SINO-PhIRDA) brings together top scientific research institutes, pharmaceutical universities, pharmaceutical schools under prestigious universities, backbone organizations in the domestic pharmaceutical research, representative innovative pharmaceutical enterprises and some clinical medical institutions in China. SINO-PhIRDA members represent the R&D capabilities of China pharmaceutical industry. SINO-PhIRDA is a R&D-based, innovation-oriented and clinical-need-driven public organization that is characterized by the close integration of enterprises, universities and research institutions and is designed to promote pharmaceutical research and development.
About PhRMA
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the leading pharmaceutical research and biotechnology companies of the United States, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA's mission is to effectively communicate and influence public policies so as to encourage the pharmaceutical and biotechnology companies to develop important new medicines. PhRMA companies are leading the way in the search for new cures. PhRMA members invested about US$49.4 billion in 2010 in developing new medicines. In China, PhRMA works closely with the RDPAC under the China Association of Enterprises with Foreign Investment. The two have basically the same members, which are all foreign-funded R&D-oriented pharmaceutical companies.
——SINO-PhIRDA and PhRMA signed the Joint Declaration on Strengthening Intellectual Property Rights Protection, Promoting Pharmaceutical Industry Innovation and Development, and Improving Public Health
On October 18, the SINO-U.S. Pharmaceutical Industry Summit 2011 was grandly held in Beijing, which was cosponsored by the China Chamber of International Commerce (CCIOC), the China Pharmaceutical Industry Research and Development Association (SINO-PhIRDA), the American International Chamber of Commerce (AICC) and the Pharmaceutical Research and Manufactures of America (PhRMA). Thanks to the coordination and supports from the American Chamber of Commerce, the China Council for the Promotion of International Trade (CCPIT) and Fosun Pharma (Shanghai), more than 200 Chinese and foreign officials, corporate executives and industry experts attended the summit. The SINO-PhIRDA and the PhRMA signed the Joint Declaration on Strengthening Intellectual Property Rights Protection, Promoting Pharmaceutical Industry Innovation and Development, and Improving Public Health at the summit, in which both parties make commitments to constantly improve the health of the two peoples by providing safe and effective new drugs to patients. Both parties agreed that a complete intellectual property rights protection system is of crucial importance in the continuous innovations of biomedical industry and that they will fulfill their commitments to patients only through continuous innovations. To ensure continuous innovation in the pharmaceutical industry and promote the industry development, both sides proposed that they should urge the government departments to formulate and implement a series of supporting policies to protect various intellectual property rights in the pharmaceutical industry.
After reaching aforesaid consensuses, SINO-PhIRDA and PhRMA expressed that they would establish closer cooperation, assist government departments in formulating and implementing the intellectual property right protection system, and foster a policy environment for the research and development of safe, effective and technology-intensive new drugs. In addition, both sides promised to facilitate the constant improvement in legal system and enhance the protection on biomedical intellectual property rights in both countries by encouraging cooperation among all stakeholders.
The SINO-U.S. Pharmaceutical Industry Summit 2011 was cosponsored by the CCOIC, SINO-PhIRDA, AICC and PhRMA. Leaders of China’s Ministry of Commerce, Ministry of Health, State Food and Drug Administration (SFDA) and CCPIT attended and delivered speeches at the Summit, and over 200 enterprise representatives and experts in the pharmaceutical industry of both countries also attended the Summit.
Mr. Sang Guowei, Vice Chairman of the Standing Committee of the National People’s Congress (NPC) and Academician of the Chinese Academy of Engineering, and Christopher Viehbacher, Chairman of Board of PhRMA, also attended the Summit and delivered speeches.
At the Summit, Chinese and American experts gave speeches or keynote reports on pharmaceutical intellectual property rights protection, pharmaceutical industry innovation and development, health rights and interests of the social public and other topics. The cosponsors of the Summit also arranged the special Roundtable on Sino-U.S. Pharmaceutical Industry IPR Protection, at which Mr. Chen Qiyu, SINO-PhIRDA Vice President and Chairman of the Board of Fosun Pharma (Shanghai) introduced the status quo and future strategies of the company, attracting high attention from the industry.
The Summit also featured luncheon and banquet dinner for the sake of exchanges and communications among the participants and guests in a relaxing atmosphere. Wan Jifei, Chairman of the CCPIT and Chairman of the CCOIC, Jiang Zengwei, CPC Deputy Secretary and Vice Minister of Commerce of the PRC, and Wang Xiaomin, envoy of the U.S. Embassy in China and deputy head of the U.S. delegation, attended the luncheon and delivered speeches.
Two SINO-U.S. Pharmaceutical Industry Summits has been held twice since 2009. The Summit has become an important exchange platform for pharmaceutical industries in both China and the U.S., where industry representatives exchange opinions on the issues and strategies of public policies so as to promote the development of R&D-oriented pharmaceutical industries in both China and the U.S.
More than 30 news agencies including such mainstream media as Xinhua News Agency, People’s Daily, Bloomberg, Associated Press, Agence France Presse and Reuters sent journalists to report and interview the Summit, which received substantial supports from the AICC, the CCPIT, and Fosun Pharma (Shanghai) etc., as well as close cooperation from the R&D-based Pharmaceutical Association Committee (RDPAC).
About SINO-PhIRDA
Founded in 1988, China Pharmaceutical Industry Research and Development Association (SINO-PhIRDA) brings together top scientific research institutes, pharmaceutical universities, pharmaceutical schools under prestigious universities, backbone organizations in the domestic pharmaceutical research, representative innovative pharmaceutical enterprises and some clinical medical institutions in China. SINO-PhIRDA members represent the R&D capabilities of China pharmaceutical industry. SINO-PhIRDA is a R&D-based, innovation-oriented and clinical-need-driven public organization that is characterized by the close integration of enterprises, universities and research institutions and is designed to promote pharmaceutical research and development.
About PhRMA
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the leading pharmaceutical research and biotechnology companies of the United States, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA's mission is to effectively communicate and influence public policies so as to encourage the pharmaceutical and biotechnology companies to develop important new medicines. PhRMA companies are leading the way in the search for new cures. PhRMA members invested about US$49.4 billion in 2010 in developing new medicines. In China, PhRMA works closely with the RDPAC under the China Association of Enterprises with Foreign Investment. The two have basically the same members, which are all foreign-funded R&D-oriented pharmaceutical companies.